Study of AP23573 in Patients With Relapsed or Refractory Hematologic Malignancies (8669-024)(COMPLETED)

Merck Sharp & Dohme LLC (Industry)
Overall Status
Completed ID
Ariad Pharmaceuticals (Industry)

Study Details

Study Description

Brief Summary

The purpose of this phase II study is to assess the efficacy of AP23573 in patients with specified relapsed or refractory hematological malignancies.

Detailed Description

The primary objective of the trial is to assess the efficacy of AP23573 in patients with specified relapsed or refractory hematological malignancies by evaluating the response rates as defined for the individual malignancy categories. Secondary objectives include evaluating time to disease progression, progression-free survival and duration of response; evaluating the pharmacokinetic and pharmacodynamic characteristics of AP23573; describing health-related quality of life measurements; and exploring the safety and tolerability of AP23573 at the specified dose level.

Protocol Outline: Open label, non-randomized parallel cohorts of five disease-specific cohorts with a minimum of 21 patients per cohort. Each patient receives a fixed dose of AP23573 administered intravenously (IV) over 30 minutes daily for five days (QDx5) to be repeated every 2 weeks.

Study Design

Study Type:
Actual Enrollment :
57 participants
Intervention Model:
Parallel Assignment
None (Open Label)
Primary Purpose:
Official Title:
A Phase II Study of AP23573, an mTOR Inhibitor, in Patients With Relapsed or Refractory Hematologic Malignancies
Study Start Date :
Jun 1, 2004
Actual Primary Completion Date :
Jun 1, 2006
Actual Study Completion Date :
Jun 1, 2006

Arms and Interventions

Arm Intervention/Treatment
Experimental: 1

AP23573 12.5 mg IV as monotherapy once daily for 5 days, every 2 weeks

Drug: ridaforolimus
AP23573 12.5 mg IV as monotherapy once daily for 5 days, every 2 weeks
Other Names:
  • deforolimus
  • AP23573
  • MK-8669
  • ridaforolimus was also known as deforolimus until May 2009
  • Outcome Measures

    Primary Outcome Measures

    1. To assess efficacy of AP23573 in patients with relapsed or refractory hematologic malignancies. [Duration of study]

    Secondary Outcome Measures

    1. Evaluating time to progression, progression-free survival, duration of response and safety [Duration of study]

    Eligibility Criteria


    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    Accepts Healthy Volunteers:

    Inclusion Criteria (Patients must meet each of the following criteria to be eligible for participation in the trial):

    • Male or female patients ≥ 18 years of age

    • Patients must have histologically-confirmed diagnoses of relapsed or refractory hematologic malignancy as specified in the protocol

    • Patients must have an ECOG performance status of 0 to 2

    • Patients must have adequate renal and liver function as demonstrated by laboratory values performed within 5 days, inclusive, prior to administration of the first dose of AP23573

    • Patients must be able to understand and give written informed consent

    Exclusion Criteria (Patients meeting any of the following criteria are ineligible for participation in the study):

    • Women who are pregnant or lactating

    • Patients may not have had cytotoxic chemotherapy or radiotherapy within 14 days prior to study entry

    • Patients may not receive any investigational anti-cancer agent while on this study or within 14 days prior to the first dose of AP23573

    • Patients with known or suspected hypersensitivity to drugs formulated with polysorbate 80 (Tween) or any other excipient contained in the study drug formulation

    • Patients with known Grade 3 or 4 hypersensitivity to macrolide antibiotics (e.g., clarithromycin, erythromycin, azithromycin)

    • Patients with significant uncontrolled cardiovascular disease

    • Patients with known HIV infection

    • Patients with any uncontrolled infection

    • Patients receiving immunosuppressive agents other than prescribed corticosteroids

    • Patients who have had prior therapy with rapamycin, any rapamycin analog or tacrolimus

    • Patients with inadequate recovery from any prior surgical procedure or patients having undergone any major surgical procedure within 14 days prior to the first dose of AP23573

    • Patients with any other life-threatening illness or organ system dysfunction which, in the opinion of the Investigator, would either compromise the patient's safety or interfere with evaluation of the safety of the study drug

    • Patients with a psychiatric disorder or altered mental status that would preclude understanding of the informed consent process and/or completion of the necessary studies

    • Patients with another primary malignancy within the past three years (except for non-melanoma skin cancer and cervical carcinomas in situ)

    • Patients with the inability, in the opinion of the Investigator, to comply with the protocol requirements

    Drugs and Other Treatments to be Excluded (The following drugs and other treatments are not permitted for patients enrolling in the study, either during or within two weeks prior to the first dose of AP23573, unless otherwise specified):

    • Chemotherapeutic agents with the following exception that therapy with nitrosoureas (including generics) cannot be given within six weeks prior to the first dose of AP23573

    • Other antineoplastic agents

    • Immunotherapy (including vaccines) or biological response modifier therapy

    • Systemic hormonal therapy with exceptions as specified in the protocol

    • Herbal preparations or related OTC preparations containing herbal ingredients (e.g., St John's Wort)

    • Radiotherapy for the primary malignancy

    • Any other investigational agent during the course of the trial should be discussed with the Sponsor prior to use

    Contacts and Locations


    Site City State Country Postal Code
    1 University of Chicago Hospitals, Section of Hematology/Oncology Chicago Illinois United States 60637
    2 Washington University School of Medicine, Siteman Cancer Center, 4921 Parkview Place St. Louis Missouri United States 63110
    3 The Cancer Institute of New Jersey New Brunswick New Jersey United States 08903
    4 New York Presbyterian Hospital, Weill College of Cornell University New York New York United States 10021
    5 Morris Cancer Center - Duke University Medical Center, Adult Bone Marrow Transplant Clinic Durham North Carolina United States 27705
    6 Gabrail Cancer Center Canton Ohio United States 44718
    7 Jeane's Hospital of TUHS Philadelphia Pennsylvania United States 19111
    8 MD Anderson Cancer Center Houston Texas United States 77030

    Sponsors and Collaborators

    • Merck Sharp & Dohme LLC
    • Ariad Pharmaceuticals


    • Study Director: Frank Haluska, M.D., Ph.D., Ariad Pharmaceuticals

    Study Documents (Full-Text)

    None provided.

    More Information


    None provided.
    Responsible Party:
    Merck Sharp & Dohme LLC Identifier:
    Other Study ID Numbers:
    • 8669-024
    • AP23573-04-201
    First Posted:
    Jun 28, 2004
    Last Update Posted:
    Aug 19, 2015
    Last Verified:
    Aug 1, 2015

    Study Results

    No Results Posted as of Aug 19, 2015